- Home
- CLMT vs EXEL Comparison
CLMT vs EXEL Comparison
Compare CLMT & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLMT
- EXEL
- Stock Information
- Founded
- CLMT 1916
- EXEL 1994
- Country
- CLMT United States
- EXEL United States
- Employees
- CLMT N/A
- EXEL N/A
- Industry
- CLMT Oil & Gas Production
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLMT Energy
- EXEL Health Care
- Exchange
- CLMT Nasdaq
- EXEL Nasdaq
- Market Cap
- CLMT 1.3B
- EXEL 12.0B
- IPO Year
- CLMT 2006
- EXEL 2000
- Fundamental
- Price
- CLMT $16.78
- EXEL $44.86
- Analyst Decision
- CLMT Strong Buy
- EXEL Buy
- Analyst Count
- CLMT 6
- EXEL 18
- Target Price
- CLMT $20.17
- EXEL $43.65
- AVG Volume (30 Days)
- CLMT 1.5M
- EXEL 3.7M
- Earning Date
- CLMT 08-08-2025
- EXEL 08-05-2025
- Dividend Yield
- CLMT N/A
- EXEL N/A
- EPS Growth
- CLMT N/A
- EXEL 237.58
- EPS
- CLMT N/A
- EXEL 2.20
- Revenue
- CLMT $4,177,500,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- CLMT N/A
- EXEL $9.37
- Revenue Next Year
- CLMT N/A
- EXEL $11.05
- P/E Ratio
- CLMT N/A
- EXEL $20.36
- Revenue Growth
- CLMT 0.68
- EXEL 24.49
- 52 Week Low
- CLMT $7.68
- EXEL $22.13
- 52 Week High
- CLMT $25.29
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- CLMT 63.02
- EXEL 56.79
- Support Level
- CLMT $15.63
- EXEL $43.21
- Resistance Level
- CLMT $17.13
- EXEL $48.74
- Average True Range (ATR)
- CLMT 0.73
- EXEL 2.01
- MACD
- CLMT -0.03
- EXEL 0.05
- Stochastic Oscillator
- CLMT 83.87
- EXEL 31.61
About CLMT Calumet Specialty Products Partners L.P. Common Units
Calumet Inc is a producer of specialty products, including base oils, specialty oils, solvents, esters, and waxes, as well as a variety of fuel and fuel-related products, including asphalt and heavy fuel oils. The company manufactures, formulates, and markets a variety of specialty branded products to customers in various consumer-facing and industrial markets. Its segments include: Specialty Products and Solutions; Montana/Renewables; Performance Brands; and Corporate. The company generates maximum revenue from Fuels, asphalt and other by-products.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.